Turning Point Therapeutics Priced, Nasdaq: TPTX

Early stage biotech developing tyrosine kinase inhibitors for treating cancer.

Industry: Health Care

Latest Trade: $28.12 +1.06 (+3.9%)

First Day Return: +60.6%

Return from IPO: +50.3%

Industry: Health Care

We are a clinical-stage biopharmaceutical company designing and developing novel small molecule, targeted oncology therapies to address key limitations of existing therapies and improve the lives of patients. Our internally developed and wholly owned pipeline of next-generation tyrosine kinase inhibitors (TKIs) targets numerous genetic drivers of cancer in both TKI-naïve and TKI-pretreated patients. The pervasive challenges of intrinsic and acquired treatment resistance often limit the response rate and durability of existing therapies. One of these challenges is the emergence of solvent front mutations, which are a common cause of acquired resistance to currently approved therapies for ROS1, TRK and ALK kinases. We have developed a macrocycle platform enabling us to design proprietary small, compact TKIs with rigid three-dimensional structures that potentially bind to their targets with greater precision and affinity than other kinase inhibitors. We believe our macrocycle platform will generate TKIs that are potentially best-in-class. Our lead drug candidate, repotrectinib (TPX-0005), is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+ or ALK+ advanced solid tumors.
more less
IPO News for Turning Point Therapeutics
more
IPO Data
IPO File Date 03/21/2019
Offer Price $18.00
Price Range $16.00 - $18.00
Offer Shares (mm) 9.3
Deal Size ($mm) $167
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 04/16/2019
Offer Price $18.00
Price Range $16.00 - $18.00
Offer Shares (mm) 9.3
Deal Size ($mm) $167
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters San Diego, CA
Founded 2013
Employees 50
Website www.tptherapeutics.com